Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $32.03M | $-81.86M | $-0.08 |
| 2025 | $27.29M | $-46.98M | $-0.05 |
| 2024 | $25.19M | $-34.53M | $-0.04 |
| 2023 | $18.93M | $-17.02M | $-0.02 |
| 2022 | $4.13M | $-18.38M | $-0.02 |
Social Signal Score
Earnings
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Mar 13$-0.01 vs $-0.01beat
Estimates and results for ZOM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ZOMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsaccessnewswire.com·4d ago·Neutral
Zomedica Announces "Fourth Friday at Four" Webinar on August 28, 2026: Zomedica International: Building a Global Platform for Veterinary Innovation August session to spotlight Zomedica's international expansion strategy, distributor infrastructure, global market opportunity, and the commercial leadership driving growth across five continents ANN ARBOR, MI / ACCESS Newswire / August 11, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative
View source ↗